About 15% of the legally blind completely lack light perception. Most of these individuals have abnormally phased circadian rhythms and many freerun. Light treatment is not an option for them. However, melatonin treatment can be highly effective. A daily dose of 0.5 mg of melatonin usually results in entrainment. It has been suggested that treatment in individuals with circadian periods > 24 h should be initiated on the advance zone of the melatonin phase response curve, which was based on findings in which melatonin initiated on the delay zone were less likely to result in entrainment, even though treatment continued across all circadian phases. In the present study, 7 totally blind people started low-dose melatonin treatment (0.5 mg; 1 person was given 0.05 mg) on the delay zone. All entrained as circadian phase free-ran and the advance zone of the melatonin phase response curve coincided with the time of melatonin administration. These results are consistent with studies in other mammals. It does not appear that low-dose melatonin treatment needs to be initiated on the advance zone to induce eventual entrainment in blind people with free-running rhythms > 24 h. Therefore, it is not essential that circadian phase be ascertained before starting low-dose melatonin treatment of blind people. Figure 1. Relationship between the endogenous melatonin profile, the melatonin phase response curve (PRC), and the sleep-wake cycle. BFR = blind free-runners; MO = melatonin onset. Modified from Lewy et al. (2001) with permission.
Despite exposure to regular social cues, meal times, and sleep/wake schedules, the circadian phase position of blind free-runners (BFRs) continues to change, usually to a progressively later time, due to the > 24 h endogenous circadian periods in most individuals Lockley et al., 1997a; Klerman et al., 1998) . Although BFRs may try to maintain normal sleep and wake times, they have recurrent bouts of nighttime insomnia and daytime sleepiness that are predicted by circadian phase (Lockley et al., 1997b; Lockley et al., 1999) and objective decrements in sleep quality as documented by polysomnography (Sack et al., 2000; Leger et al., 2002) , as the sleep propensity rhythm moves in and out of phase with scheduled bedtimes-a burden described by some as second only to lack of vision. Inspired by studies in rodents (Redman et al., 1983) , more than a decade ago we attempted to entrain BFRs to a bedtime dose of 5 mg given for 3 weeks (an FDA limitation at that time) (Sack et al., 1991) . Phase-advance shifts in the melatonin onset (MO) resulted, but they were not sufficient for entrainment. We were, however, able to document apparent entrainment in a BFR who on his own had been taking about 7.5 mg of melatonin at bedtime for a year (Sack et al., 1990) .
More recently, when the treatment regimen was changed to 10 mg administered for 3 to 9 weeks, 6 of 7 BFRs entrained: the BFR who did not entrain had the longest free-running period (tau = 24.9 h); melatonin (10 mg) was only able to provide a 0.6 h daily phase advance (Sack et al., 2000) . In 3 BFRs, the dose was stepped down to 0.5 mg-without loss of entrainment (Sack et al., 2000) . We further showed that BFRs could be entrained to a de novo dose of 0.5 mg melatonin (Lewy et al., 2001) . In all of the above cases, exogenous melatonin was initiated around the time when the endogenous MO was expected to occur, which is on the advance zone of the melatonin phase response curve (PRC). A research group from the University of Surrey demonstrated entrainment in about half of 7 BFRs using a daily melatonin dose of 5 mg (Lockley et al., 2000) and in 6 of 10 BFRs using 0.5 mg (discussed below) (Hack et al., 2003) .
Although the melatonin PRC was experimentally determined in sighted individuals Zaidan et al., 1994; Middleton et al., 1997; Lewy et al., 1998a ), it appears to apply to blind people as well ( Fig. 1) . In sighted people, who are normally entrained to the 24 h day, when melatonin is administered in the afternoon and evening, it causes a phase advance. If administered very late at night and in the morning, it causes a phase delay.
The phase-advance and phase-delay zones of the melatonin PRC are easily delineated in sighted people using the dim light melatonin onset (DLMO) as a marker of circadian phase to calculate circadian time. By convention, CT 0 is defined as waketime in sighted people; since the plasma 2 pg/ml DLMO (DLMO 2 ) occurs 13 h later, we define it as CT 13 (the plasma 10 pg/ml DLMO [DLMO 10 ] occurs 1 h later and is defined as CT 14). Salivary levels around the DLMO are about 1/3 those of plasma (Miles and Philbrick, 1987) , and so a salivary threshold of 0.7 pg/ml corresponds to the plasma DLMO 2 . The plasma MO 2 is also designated CT 13 in blind people (because melatonin does not need to be collected under dim light conditions in the blind, we simplify the acronym to MO). In the following, we will refer to the DLMO 2 and MO 2 as DLMO and MO, respectively.
The phase-advance zone extends from CT 6 to CT 18, and the phase-delay zone extends from CT 18 to CT 6. In other words, the advance zone extends from 7 h Lewy et al. / CLINICAL IMPLICATIONS 69 The end of the DELAY zone of the melatonin PRC is seven hours before the 2 pg/ml MO.
The greatest phase advances occur when exogenous melatonin is given here.
The endogenous melatonin profile and the melatonin PRC shift later after each day in a BFR, relative to clock time and sleep.
The end of the ADVANCE zone of the melatonin PRC is five hours after the 2 pg/ml MO.
Relationship between the sleep/wake cycle and the endogenous melatonin profile/melatonin PRC, when the latter has drifted into the normal entrainment phase.
The 2 pg/ml MO occurs three hours before sleep during normal entrainment. The earlier melatonin is given in the second half of the phase-advance zone, the greater the phase advance-before the magnitude of phase advances decline and the crossover point is approached-and crossing over will result in a phase delay. When melatonin is given at the same clock time each day to a typical BFR (circadian period > 24 h), circadian phase will continue to shift later until exogenous melatonin hits the part of the PRC that produces a phase advance equal to the daily drift (this is called the entrainment point and will vary between individuals, depending in part on their tau). For example, if tau is 24.4 h, exogenous melatonin will stop the pacemaker from drifting when it stimulates that part of the PRC such that a phase advance of 0.4 h is produced. The pacemaker now has a functional tau of 24.0 h and is entrained. By assessing the MO the day before melatonin treatment is initiated, one can estimate the circadian time when melatonin is given the next day. For example, if the clock time of administration is 2200 and the MO occurred at 0800 the previous day, then the circadian time of administration was about CT 3 (on the delay zone of the PRC).
What would be predicted if melatonin treatment were on the "wrong" zone of the melatonin PRC, particularly in BFRs? According to animal studies, it does not matter when the stimulus is initially given (Pittendrigh and Daan, 1976) . Entrainment will eventually occur once the entrainment point on the PRC drifts into contact with the stimulus (Redman et al., 1983) .
However, the Surrey group found that initiation of melatonin administration on the delay zone in individuals with circadian periods > 24 h may compromise entrainment in BFRs (Lockley et al., 2000) : about half of 7 BFRs entrained to a daily dose of 5 mg when melatonin was initiated on the advance zone; the other BFRs failed to entrain when melatonin was started on the delay zone, even though they free-ran through at least 1 complete circadian beat cycle, thus exposing all of the advance zone to exogenous melatonin. This research group hypothesized that either initiation of treatment on the delay zone may lead to changes in the melatonin PRC that compromise eventual entrainment or that melatonin administration may affect melatonin receptor sensitivity. They noted that this explanation was in contradistinction to animal studies of melatonin and light zeitgebers. If true, the clinical implications are enormous, because if melatonin must be initiated on the advance zone, then BFRs can only be treated after their endogenous MO or some other marker for the phase of the melatonin PRC is assessed on multiple occasions. We show here, however, when treatment is initiated on the delay zone of the PRC with low doses (≤ 0.5 mg) of melatonin, entrainment eventually occurs. Note: in a more recent study (Hack et al., 2003) , the Surrey group identified some BFRs who did entrain when melatonin (0.5 mg) was initiated on the delay zone; however, they continue to find that entrainment is more likely if melatonin is initiated on the advance zone.
MATERIALS AND METHODS
Seven totally blind adults were recruited from blind advocacy organizations and by referral within the blind community. Information about the study was provided to the subjects in print and Braille, and on audiotape; subjects gave written informed consent. The Institutional Review Board of Oregon Health & Science University (OHSU) approved the protocol and the consent forms. See Table 1 for subject demographics. Subject 1, 4, and 7 have been studied previously: in our previous report, Subject 1 was listed as Subject 7, Subject 4 was Subject 2, and Subject 7 was Subject 5 (Sack et al., 2000) . None of the results pre- sented here have been published previously, except as an abstract (Emens et al., 2003) . Subjects were admitted at approximately 2-week intervals to the General Clinical Research Center of OHSU for circadian phase assessments. For each assessment, blood or saliva was sampled hourly for 24 h to determine the plasma or salivary MO, operationally defined as the interpolated time when levels rose continuously above the threshold of 2 pg/ml for plasma (Subjects 1, 2, 4, and 5) and 0.7 pg/ml for salivary melatonin (Participants 3, 6, and 7). Based on our previous pharmacokinetic data for the 0.5 mg dose (Lewy et al., 1998a) , melatonin was not taken on the day of melatonin sampling, so that there would be no interference from exogenous melatonin. During each admission, no restrictions were placed on posture (although subjects were recumbent most of the time). We think that the effects of posture on melatonin levels remain unclear: 2 groups have reported a modest increase in melatonin levels when subjects change their posture from supine to standing (Deacon and Arendt, 1994; Nathan et al., 1998) , another reported a modest decrease in the subjective day during a forced desynchrony protocol under dim light conditions (Shanahan and Czeisler, 2000) , and a fourth group reported no effect (Voultsios et al., 1997) . Subjects were not allowed to engage in physical exercise, but otherwise no restrictions were made on physical activity. In addition, there was no imposed structuring of lighting conditions, sleep schedules, and meals during admissions, and subjects were not placed in temporal isolation.
After baseline assessment of the free-running circadian period, subjects were administered 0.5 mg (and in one case 0.05 mg) melatonin by mouth nightly approximately 1 h before their preferred bedtime. Subjects were not aware if they were receiving melatonin or placebo, nor were the nurses or the RIA technician. No baseline placebo control was used. The timing of melatonin administration was chosen to approximate the normal phase relationship between the endogenous MO and the sleep-wake cycle (Lewy et al., 1998b) . Analytic grade melatonin (administered under Investigational New Drug Application 26,318) was obtained from Regis Chemical (Morton Grove, IL) and was formulated under a pharmacist's supervision in gelatin capsules with a lactose filler. The capsule containers were coded and were labeled individually for each day of treatment in both print and Braille. To assess compliance, capsule containers were returned with each admission to the General Clinical Research Center, any remaining capsules were noted, and new capsule containers were issued. Subjects were also instructed to report any missed pills. Subjects 1 and 2 missed no capsules, Subject 3 missed 16, Subject 4 missed 2, Subject 5 missed 5, Subject 6 missed 1, and Subject 7 missed 4. Treatment was begun when the MO was predicted to occur at an hour when melatonin administration before bedtime would be on the delay zone of the melatonin PRC (CT 18-6). Treatment was initiated 1 to 2 days after an assessment of circadian phase (6 days afterward in the case of Subject 5). The circadian time of initial administration was determined later by interpolation between the phase assessment just before and the phase assessment just after treatment was initiated.
Entrainment was defined as a circadian period, calculated by linear regression through all MOs after beginning treatment, with 95% confidence intervals that overlapped 24 h. Subject 1 had only two free-running data points, so no pretreatment 95% confidence interval is provided, and Subject 3 had a pretreatment circadian period with a 95% confidence intervals that overlapped with 24 h. Both were considered to be freerunning because of their long taus (25.02 h and 24.45 h, respectively), as well as the abnormal phases of all of their pretreatment MOs. Entrainment was not further verified by release of the subjects into free-run to rule out masking effects; this has been consistently demonstrated in previous melatonin treatment studies of BFRs (Sack et al., 1999; Lockley et al., 2000; Sack et al., 2000) . Pretreatment circadian periods were calculated by linear regression through all MOs prior to beginning treatment with exogenous melatonin. The final postentrainment circadian periods were calculated by linear regression through all MOs with a negative phase angle of entrainment (MOs occurring after the capsule administration time) after beginning treatment. This was done to avoid overestimating the postentrainment tau due to inclusion of data points while melatonin was being administered on the delay zone; also, all subjects had taus > 24 h and would therefore be expected to have a negative phase angle once entrainment had occurred.
After entrainment was accomplished, the timing of melatonin administration was advanced by either 1 h approximately every 2 weeks (14 to 19 days, Subject 1) or by a half-hour approximately every week (5 to 7 days, Subjects 3, 4, and 5). Subject 2 dropped out of the study prior to the planned advance of his administration time, and Subjects 6 and 7 have yet to be advanced. The administration time was moved earlier to advance circadian phase, so that the MO would occur at a more normal clock hour relative to the sleep to wake/cycle (i.e., the MO occurring 2 to 3 h before bedtime).
Plasma and salivary melatonin concentrations were measured by radioimmunoassay with an antibody raised in the laboratory of Kennaway and coworkers and reagents supplied by American Laboratory Products (Windham, NH) (Earl et al., 1985; Voultsios et al., 1997) . The lower limit of sensitivity of the plasma and saliva assay is 0.3 pg/ml. Other performance characteristics of these RIAs are available from the manufacturer. This assay was validated by GCMS (Lewy and Markey, 1978; Lewy et al., 1997) .
RESULTS
Eventually, all 7 subjects successfully entrained to 0.5 mg (and in 1 subject 0.05 mg) begun on the delay zone of the melatonin PRC (Fig. 2) . The average (± SE) pretreatment circadian period (24.51 ± 0.09 h) was significantly different from the average postentrainment circadian period (23.99 ± 0.01h) (p < 0.01, t = 5.887, df = 6). Melatonin was always initiated on the delay zone (between CT 20.81 and CT 4.49). The CTs and clock times of initial administration, as well as the preentrainment and postentrainment taus, are given in Table 2 . In some instances, the postentrainment taus were less than 24 h due to advancing the capsule administration time. Incidentally, inclusion of all posttreatment MOs in the calculation of postentrainment taus continued to yield postentrainment period estimates with 95% confidence intervals that overlapped with 24 h for all subjects. In all cases, subjects did not entrain until their PRCs had shifted such that the time of melatonin administration was on the phaseadvance zone. This is most apparent by noting, in Figure 2 , that entrainment occurs when the administra-tion time is just before the MO in all subjects and by recalling that the advance zone begins 7 h before the MO and ends 5 h after the MO. Although Subjects 2 and 4 initiated treatment near the transition between the advance and delay zones, their > 24 h taus required them to free-run through almost all of the delay zone before melatonin administration occurred on the advance zone (resulting in entrainment). Subjects quickly achieved a relatively stable phase angle of entrainment to melatonin (0 to -3.5 h), with the exception of Subject 3 who not infrequently missed her melatonin dose and had phase angles of entrainment of -0.3 to -9.0 h (Fig. 2) .
DISCUSSION
Consistent with animal studies (Pittendrigh and Daan, 1976) , the PRC free-runs until its entrainment point eventually comes into contact with the phaseshifting stimulus, even if the latter is initiated on the delay zone. The fact that it is not necessary to initiate melatonin administration on the advance zone of the melatonin PRC implies that many BFRs can be treated with ≤ 0.5 mg melatonin without having to measure their MOs. Individuals who remain symptomatic with either continued complaints of recurrent daytime somnolence and nighttime insomnia (possibly indicating continued free-running) or those who have chronic complaints of insomnia or excessive daytime somnolence (possibly indicating entrainment to an abnormal phase position) may require assessment of circadian phase. In addition to determining tau, assessment of the MO definitively indicates when entrainment has occurred, as well as the phase position of the PRC.
If treatment initiation phase does not explain why more of the Surrey group's cohort of BFRs did not entrain to the 5-mg dose of melatonin, what other 72 JOURNAL OF BIOLOGICAL RHYTHMS / February 2004 explanations come to mind? We hypothesize that the failures with the 5-mg dose, like our own failure in one BFR with the 10-and 20-mg doses (Sack et al., 2000; Lewy et al., 2002) , can be explained by consideration of the melatonin PRC ( Fig. 1) Lewy et al., 1998a) . Higher doses of exogenous melatonin, administered on the advance zone, may result in sustained, elevated levels of melatonin that stimulate both the advance and delay regions of the melatonin PRC, resulting in smaller net daily phase advances. BFRs who begin treatment on the advance zone (or who begin treatment on the delay zone and free-run until administration occurs on the advance zone) may not entrain if "spillover" of exogenous melatonin onto the delay zone results in phase advances of insufficient magnitude for entrainment (Lewy et al., 2002) . In individuals with relatively short circadian periods, such spillover effects may be less relevant since the required phase advance is small. In individuals with longer circadian periods (e.g., 24.9 h), spillover may become more important, since the requisite daily phase advance for entrainment is larger (Lewy et al., 2002) . Such spillover effects may be dependent on individual pharmacokinetics, as well as dose. Even some BFRs with short zone circadian periods conceivably could fail to entrain due to spillover effects. Perhaps our past difficulties with the 5-mg dose can also be explained in this way, although we continue to think that 3 weeks may be too short a treatment duration for some people: when melatonin stimulates the advance zone, it slows the rate at which the entrainment point drifts into contact with the treatment dose, because the phase advances, while not always sufficient for entrainment, oppose the daily phase delays. Indeed, the Surrey group speculated that the duration of treatment may have been too short in their nonentrained subjects as well, even though they were treated for one circadian beat cycle (Lockley et al., 2000) . It should be noted as an aside that the opposite is also true: when melatonin stimulates the delay zone, it speeds the rate of drift as indicated in Figure 2 .
In any event, entrainment should occur within a few months, if it is going to occur at all. We agree with Lockley and colleagues (2000) that further studies designed to show that entrainment is less likely to occur when melatonin treatment is initiated on the delay zone would include-after failing on the delay zone-a repeat trial of the identical dose in the same BFR given on the advance zone. We would also note that Subject 7 entrained to 0.05 mg melatonin. This is one of the lowest doses of melatonin used in human studies to date, and further data on the efficacy of very low doses is forthcoming.
Limitations of our study include the lack of a placebo baseline group; however, placebo groups were included by us and others previously in the entrainment of BFRs (Lockley et al., 2000; Sack et al., 2000) . Release into free-run after entrainment, which would rule out masking effects, was not done, although we and others have also done this previously (Sack et al., 1999; Lockley et al., 2000; Sack et al., 2000) . Initiation of treatment 6 days after assessment of circadian phase in Subject 5 decreases the accuracy of our estimation of the CT of initial administration; however, CT 1.05 is close to the center of the delay zone (CT 0), increasing the likelihood that melatonin was initiated on the delay zone. We used both plasma and salivary melatonin in our assessments of circadian phase; however, each subject was assessed using only 1 of these and the 2 have been shown to highly correlate (McIntyre et al., 1987; Voultsios et al., 1997) . We do not know if our results would be applicable to sighted individuals with non-24-h sleep/wake schedule disorder. Finally, we only used 1 marker of circadian phase; however, it is the general consensus that the melatonin and temperature rhythms (Shanahan and Czeisler, 1991) , as well as the melatonin and cortisol rhythms , are phase locked.
